by 
Market Overview:
Epidermolysis bullosa (EB) refers to a group of rare inherited disorders characterized by easy blistering of the skin and mucous membranes. The main symptoms include blistering or wounds in the skin and mucous membranes. The severity of disease varies from very mild to severe forms that can affect internal body organs. Epidermolysis bullosa is treated symptomatically through wound care, pain management and preventing complications. The advanced cell-based therapies like gene therapy and stem cell therapy are emerging as promising treatments to cure this genetic disorder.
The Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn or Bn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing research and development activities in cell therapy is a key driver for the epidermolysis bullosa market growth. Major players are focusing on R&D for developing advanced cell therapies as a permanent cure for EB. For instance, Abeona Therapeutics is developing gene therapy treatment (EB-101) targeting recessive dystrophic epidermolysis bullosa. Increasing awareness about advanced treatment options and government support for orphan drug development further support the market growth over the forecast period.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/epidermolysis-bullosa-therapeutics-market-2214
Segment Analysis
The Epidermolysis Bullosa market can be segmented into dystrophic epidermolysis bullosa (DEB) and junctional epidermolysis bullosa (JEB) on the basis of form of disease. DEB segment currently dominates the market due to rising cases of DEB worldwide. DEB is caused by genetic defects in COL7A1 gene and is characterized by fragile skin and blister formation.
PEST Analysis
Political: Governments worldwide are raising awareness about rare diseases like Epidermolysis Bullosa which is augmenting research activities. Some regions also provide financial assistance for treatment of such conditions.
Economic: Growth in research funding from private institutions and rise in healthcare expenditure is fueling market expansion. However, high treatment costs pose a challenge.
Social: Increasing social media influence is helping patients connect with support groups and latest treatment developments. Also, non-profit organizations are working to give emotional support.
Technological: Advancements in gene and cell therapies hold promise for EB treatment. Development of techniques like CRISPR is opening new avenues.
Key Takeaways
The global Epidermolysis Bullosa market is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing research into advanced treatment modalities.
Regional analysis
North America dominates the EB market backed by continual funding for research activities, adoption of advanced treatments, and supportive initiatives by government and non-profit bodies in the US and Canada. Europe also captures a significant share due to rising EB prevalence and acceptance of novel therapies in countries like Germany and the UK.
Key players
Key players operating in the Epidermolysis Bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma is a frontrunner due to its diversified EB treatment Filsuvez under review by regulatory bodies in the US and EU.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
